Pharmaceuticals Division growth over the next 5 years expected to be driven by portfolio of recently launched products
- Division had 7 blockbusters in portfolio in 2011 and expects to achieve 14 or more blockbusters by 2017
- 9 key regulatory milestones achieved so far in 2012
- Over the next 12 months, data read out of 13 late-stage pipeline projects, 9 filings and up to 7 regulatory decisions expected
- Oncology pipeline, AIN457 and heart failure (LCZ696 and RLX030) expected to provide significant newsflow; filing of RLX030 planned to commence in early 2013 in US and EU
- LAMA/LABAs, including QVA149 have potential to become new standard of care for COPD
Oncology business aims to grow through Glivec patent expiry
- Robust late stage pipeline including 13 new chemical entities and 19 new indications
- Oncology late-stage pipeline products expected to contribute more than USD 1 billion in sales by 2017
- Afinitor now expected to contribute USD 2 billion sales in advanced breast cancer alone by 2017
- Start of broad scale clinical development program announced for leading PI3K inhibitor BKM120 across multiple indications (PRISM
